S eptic shock and the ensuing multiple organ dysfunction is one of the leading causes of death of patients admitted to intensive care units (ICUs) (1) (2) (3) . Despite advances in the diagnosis and management of disease, the frequency of sepsis and septic shock continues to increase. Conventional therapy has been unable to reduce the high mortality rate (approximately 40% to 60%) observed in patients with septic shock (4).
Sepsis is best described as a systemic inflammatory response of the body to invading organisms. In sepsis, the inflammatory response is an attempt by the body to ward off pathogens but it is often uncontrolled and detrimental, which may lead to irreversible functional and structural damage to various organ systems of the host (5) . It is generally accepted that tissue damage in inflammatory conditions is caused primarily by host effector cells, rather than by the initiating agent, i.e., bacteria, endotoxin, etc. (6) . The number of organ failures that can be assessed reflects the degree of tissue damage produced by this inflammatory response daily by using criteria defined by Knaus et al (2, 7) . It is well established that the greater the degree of organ dysfunction produced by septic shock, the greater the resultant mortality (8) . Clinical experience shows that treatment of late septic shock with significant organ dysfunction is invariably disappointing, whereas appropriate early intervention is more likely to result in a favorable outcome.
Several studies have shown immunosuppressive activity of azole antifungal agents (9 -14) . The imidazoles have been shown to interfere with neutrophils and lymphocyte function. The exciting discovery that ketoconazole (which was described as a "magic potion"), an imidazole used as an antifungal agent, could reduce the frequency of adult respiratory distress syndrome (ARDS) in high-risk patients, many of whom had sepsis/septic shock, was considered an important advance (15) (16) (17) . The protective effect of ketoconazole has been attributed to its ability to inhibit thromboxane A 2 synthetase (18) . Thromboxane A 2 has been shown to have a direct role in cardiopulmonary dysfunction during graded bacteremia and is necessary to the pathogenesis of pulmonary permeability edema but is not in itself sufficient to induce these changes (19) . Itraconazole and miconazole, both antifungal azole derivatives, are potent inhibitors of 5-lipoxygenase (20) . Plasma thromboxane and leukotriene levels are both virtually unaffected by fluconazole (20) .
Fluconazole, although quite different in chemical structure (two triazole rings instead of one imidazole ring), has many similar properties to ketoconazole. However, Zervos et al. (21) showed that fluconazole had a marked effect on the bactericidal activity of neutrophils after these were exposed to fluconazole in vitro. This bactericidal effect may have occurred through a noncytokine-mediated pathway (22) . The activity of fluconazole in augmenting the bactericidal activity of neutrophils was suggested by Zervos et al. (22) as an explanation of improved survival of critically ill patients receiving this drug. Salartash and coworkers (23) reported that infusion with fluconazole significantly reduced sepsisinduced pulmonary complications in swine. Unlike ketoconazole, which is available only as an oral preparation, fluconazole can be administered intravenously. Ketoconazole intestinal absorption may be impaired in patients with septic shock (particularly in intraabdominal sepsis). This observation was supported by Yu and Tomasa (16) who showed that lower blood levels of ketoconazole in patients at high risk of ARDS were associated with development of more respiratory dysfunction.
Zervos et al. (22) and Salartash et al. (23) suggested that clinical trials with fluconazole in sepsis were warranted. In view of these observations, a double-blind trial of fluconazole in two groups of early septic shock patients was undertaken.
MATERIALS AND METHODS
All patients admitted to our ICU and diagnosed to be in early septic shock (within 24 hrs of onset) from either intra-abdominal sepsis or nosocomial pneumonia were randomized by a closed envelope system in our pharmacy to receive 200 mg of fluconazole daily in 100 mL of isotonic saline over 1 hr by intravenous infusion (test group), or 100 mL of isotonic saline alone by intravenous infusion over 1 hr (placebo group) for the duration of their septic shock. A dose of 200 mg/day intravenously of fluconazole was selected because of recommendations in the British National Formulary (24) which suggests a daily dose of 200 -400 mg for intravenous administration. The lower dose was preferred because of the long half-life of fluconazole and the suggestion that high doses of fluconazole may induce adrenal insufficiency (25) . The recent trend of supporting patients who failed to respond adequately to inotropes in septic shock with steroids (26) was not followed in this study.
Doctors and nurses were unaware of treatment randomization. The following groups of patients were excluded from the study: pregnant women; patients aged Ͻ16 yrs; patients with cirrhosis of the liver, underlying malignancy, or neurologic failure (Glasgow Coma Scale score Ͻ6); or any patient considered as having a hopeless prognosis, i.e., any patient unlikely to survive 30 days.
This study was approved by our Hospital Research and Ethics Committee and all relatives gave written informed consent. All intravenous fluconazole used in this study came from our routine pharmaceutical stock.
The criteria established by the American Society of Chest Physicians/Critical Care Society Consensus Conference were used for the diagnosis of septic shock (27) . All shock patients had a pulmonary artery catheter inserted and a profile consisting of cardiac index, systemic vascular resistance index (SVRI), pulmonary capillary occlusion pressure, and mixed venous saturation determined at least twice daily. A low SVRI was regarded as the hallmark of septic shock accompanied by clinical and microbiological evidence. All patients in this study had an SVRI Յ1200 dynes·sec/ cm 5 /m 2 . The cause of the septic shock was documented in each patient as well as the approximate duration of the process before the commencement of ICU treatment.
Clinical data to calculate Acute Physiology and Chronic Health Evaluation II scores (28) and the presence or absence of organ failures (7), and multiple organ dysfunction scores (8) were collected daily. The international normalized ratio, reference range 0.8 -1.2, was also determined daily. All biochemical and hematologic data were performed in our hospital laboratories. All patients with septic shock had a pulmonary artery catheter inserted as mentioned above and the course of shock was followed by changes in cardiac index, SVRI, pulmonary capillary occlusion pressure, and mixed venous saturation. Optimal colloid filling by monitoring of the pulmonary capillary occlusion pressure enabled blood volume to be suitably expanded. Patients who responded well to treatment, as evidenced hemodynamically by an increase in SVRI and mean arterial pressure, had their noradrenalin progressively reduced. Patients with a mean arterial pressure Ͼ70 mm Hg without catecholamine support were considered as recovered from septic shock. The duration of septic shock was defined from the time noradrenalin, which was our inotrope of choice in septic shock, was commenced to its termination. Patients were followed up until death or discharge from hospital. A patient was deemed to have survived if death did not occur before the 30th day after the commencement of treatment for septic shock.
Our antibiotic policy in patients with septic shock attributed to intra-abdominal sepsis was to commence conventional doses of piperacillin/tazobactam and gentamicin empirically and to change these antibiotics according to isolated microorganism growth and sensitivity patterns, whereas in patients with nosocomial pneumonia, we commenced piperacillin/ tazobactam empirically. If there was no satisfactory response to antibiotic therapy after 48 hrs, we switched to our "second line" antibiotic, meropenem, combined with an aminoglycoside. The organism considered to be responsible for septic shock was documented in all patients.
Yeast growth was monitored from various sites including respiratory tract, blood, urinary tract, in addition to peritoneal cavity and other tissues when appropriate in all the patients. We monitored upper and lower respiratory tracts, blood, and urinary tract at admission and then at least weekly or as clinically indicated. Local infection was defined as growth of candida from mucosal surfaces. Disseminated candidiasis was defined as presence of candida in the blood (candidemia) or histologic evidence of invasive disease in two or more organs or aseptic body fluids.
ARDS was defined according to the Acute Respiratory Distress Syndrome Consensus Conference (29) . Nosocomial pneumonia was defined by means of the clinical pulmonary infection score (30): a score of Ͼ6 was indicative of pneumonia and quantification (Ն10 3 CFU) of a known pathogen cultured from the lower respiratory tract. Blind bronchial sampling for lower respiratory tract collections was performed using a sterile catheter with a specimen trap kit (534-16, Vygon, Ecouen, France) (31) . The sensitivity of blind bronchial suctioning has been shown to be significantly higher (p Ͻ .05) than that of protected sample brushings (32) . Because blind bronchial suctioning is more sensitive and noninvasive than protected sample brushings, we favor it for diagnosis of nosocomial pneumonia. The method of scoring the clinical pulmonary infection score is shown in the Appendix. A drug history was taken to determine whether nonsteroidal antiinflammatory drugs or cortico-steroids had routinely been ingested before the acute illness.
All patients' blood sugar was monitored 4 hourly by nursing staff at the bedside. We endeavored to maintained patients' blood sugar in the range 5-7 mmol/L with intravenous insulin using a dynamic protocol.
Statistical Analysis. Results were expressed as means Ϯ standard errors of the means (SEM). "Student's" independent twosample Student's t-test, analysis of variance, regression computations, chi-squared tests, and Fisher's exact test were used where appropriate. SPSS (SPSS Inc., Chicago, IL) was used for all computations.
RESULTS
During a 2.5-yr period, December 1998 -June 2001, 71 patients with septic shock attributed to either nosocomial pneumonia or intra-abdominal sepsis were admitted to our ICU and met the criteria of early septic shock and were entered into this study. These 71 septic shock patients represented 5% (71/1,425) of total admissions during the period. For patients who had more than one episode of sepsis, only the first was used for analysis. Examination of the entry characteristics of the patients in this study demonstrated that the numbers of patients in the four clinical categories/treatment groups were not significantly different (Table 1) . Patients affected by chronic ill health in relation to treatment group and clinical categories are shown in Table 2 . Chronic ill health conditions were pooled to two classes, namely, immunologic and others (Table 3 ) and no significant differences in the dispositions in the four patient groups were revealed. The sex distribution (Table 4) was also not different in the four groups. Ages were bimodally distributed with an antimode at 50 yrs. The disposition of patients with regard to age was Ͻ50 yrs treatment group 17, Ͻ50 yrs control group 17, Ͼ50 yrs treatment group 16, Ͼ50 yrs control group 21 (Fisher's exact, p ϭ .632).
The source of infection in the 34 surgical patients with intra-abdominal sepsis is shown in Table 5 . Viscus perforation occurred most often from the large bowel because of a complication of diverticulitis or bowel anastomosis leakage in eight cases, intestinal obstruction in four cases, and single cases of gunshot wound, steroid-induced cytomegalic virus infection, stabbing, and iatrogenic perforation of uterus. Small bowel perforation/necrosis occurred because of superior mesenteric infarction in three and trauma in three patients. Two cases of "late" diagnosis of gastric leak occurred associated with gastric surgery in morbidly obese patients undergoing laparoscopic vertical banding gastroplasty. Six patients developed abscesses in the lesser sac or retroperitoneal space as a complication of severe acute pancreatitis. Two patients presented late after rupture of appendicular abscesses. One patient developed a biliary peritonitis after surgery for common bile duct stenosis. Associated conditions in the 37 pneumonia patients are demonstrated in Table 6 .
Seven biochemical and hematologic variables in addition to Acute Physiology and Chronic Health Evaluation II (28) and multiple organ dysfunction scores (8) on day one of septic shock were subjected to unpaired Student's t-tests to compare treatment and control patients (Table 7) . There were no significant differences between the two groups. Fisher's exact (two-sided), p ϭ .816. Among the total study population of 71 patients, 30- (Fig. 1) .
Although we took a 30-day survival after the commencement of septic shock as the criterion for survival, it is important to note that of a total of 25 patients who survived 30 days in the fluconazoletreated group, 21 (84%) were discharged home well, giving a hospital survival of 66% (21/ therefore duration of fluconazole administration, in the 37-patient pneumonia group (fluconazole-treated 9.3 Ϯ 1.9 days vs. placebo 6.9 Ϯ 1.0 days) was not significantly different from the 34 patients with intraabdominal sepsis (fluconazole-treated 9.6 Ϯ 1.7 days vs. placebo 6.9 Ϯ 0.6 days). The behavior of biochemical and hematologic variables during the course of the illness was investigated. Data from the first ten days in the ICU were used to show the trend before the number of patients available to study became too attenuated either by death or transfer from ICU to the general wards. By the tenth day, 66% (21/32) of patients in the fluconazole group and 59% (23/39) in the placebo group remained on the ICU.
A univariate analysis of variance was performed using each of the laboratory and physiologic variables in turn as the dependent variable, and treatment day (1-10 days) and treatment group (fluconazole or placebo) as the independent variables. For the following three variables, the computed p value for treatment group was Ͻ.0001: total white blood cell count, serum creatinine, and serum bilirubin concentrations. In the fluconazoletreated patients, the white blood cell counts were higher, and serum creatinine and bilirubin concentrations were lower than in controls (Fig. 2) . However, there was no difference between white blood cell counts of survivors or nonsurvivors who received fluconazole (p ϭ .512). The relationship of white blood cell count to presence (28 patients) or absence (43 patients) of positive blood cultures showed no significant difference between the four groups, i.e., fluconazoleand placebo-treated, pneumonia, and intra-abdominal sepsis (analysis of variance between groups F ϭ .78, p ϭ .38).
The frequency of ARDS on day 1 in patients with intra-abdominal sepsis was 41% (14/34) compared with 47% (17/37) in the pneumonia group of patients (Fisher's exact test, p ϭ .81). The frequency of ARDS was 51% (19/37) in the placebo-treated compared with 35% (12/ 34) in the fluconazole-treated group of patients (Fisher's exact test, p ϭ .236) All the organisms grown from microbiological material and considered to be responsible for the septic shock state are presented in Table 9 . The frequency of local disease caused by yeasts on the first day of ICU admission was 6% (4/71) of all patients. The frequency of local infection caused by yeasts (vide supra) on septic shock day 1 was similar in the fluconazole-treated compared with the placebo group with two patients in each group. Subsequently, during the course of stay of the placebo group, local infection occurred in a further 5% (2/37) of patients. Local disease from yeasts occurred once in respiratory and urinary tracts, respectively, during the period of septic shock. However, only one patient in the fluconazole-treated group grew a yeast organ- Figure 1 . Kaplan-Meier survival curves to demonstrate effect of fluconazole compared with placebo on outcome of septic shock attributed to intra-abdominal sepsis (top), log rank statistic ϭ 6.75, degrees of freedom ϭ 1, p ϭ .0094; nosocomial pneumonia (middle), log rank statistic ϭ 1.13, degrees of freedom ϭ 1, p ϭ .2887; and intra-abdominal sepsis and nosocomial pneumonia combined (bottom), log rank statistic ϭ 6.96, degrees of freedom ϭ 1, p ϭ .0083.
ism while receiving fluconazole. This patient grew yeast organisms (Candida nonalbicans) in the respiratory tract. No patient was considered to have disseminated candidiasis on the first day of their septic shock or subsequently during the course of their ICU stay except for one patient in the placebo group who was demonstrated to have systemic candidiasis at admission to ICU and was treated with amphotericin. No patient in this study with intra-abdominal sepsis grew yeast from his or her peritoneal cavity during the period of septic shock.
None of the patients in this study received nonsteroidal antiinflammatory drugs or steroids for their septic shock state.
DISCUSSION
There was a highly significant increase in survival of fluconazole-treated as compared with placebo-treated in these septic shock patients (Table 8) . We have demonstrated that the initial status presentation of patients in the fluconazole and control groups in regard to severity of illness, age, sex, chronic ill health, and the recorded day 1 variables were similar (Tables 1-7) . We collected only 71 patients because of the mortality difference demonstrated in the two arms of the study. No power study could be performed because we had no information on which to base this.
The survival rate in the placebo group, although low (46%), was in line with our previous experiences (41%) of patients with septic shock in our ICU (33, 34) . Our low survival rate in conventionally treated septic shock patients may relate to a high frequency of chronic ill health (49%), late transfer from referring hospitals (14%), and old age (52% Ͼ50 yrs) in our study population. The protective effect of fluconazole was accompanied by a significantly reduced number of organ failures as compared with those receiving placebo. Patients treated with fluconazole exhibited higher blood leukocyte counts, and lower serum creatinine and serum bilirubin concentrations compared with control patients (Fig. 2) .
Our only measurement of resource utilization was length of ICU stay. Length of stay was significantly greater in the survivors than the nonsurvivors, the inference being that patients died rapidly of their septic shock and multiple organ failure whereas patients who survived took a longer time to recover and convalesce. There were more patients who survived in the fluconazole-treated (78%) than the placebo-treated group of patients (46%) and this probably explains the longer fluconazole group stay compared with the placebo group although that difference was not statistically significant.
The available information clearly points to the protective effect of fluconazole in this study being unrelated to its antifungal activity. Overall, disseminated candidiasis is rare in our ICU and we see only a few cases per year. During the 2.5 yrs of this study, a total of 1,425 patients were admitted to our ICU among whom 325 isolates of yeasts were cultured. Of these isolates, only eight cases of candidemia and 12 of invasive candidiasis were recorded during the period of this study among these 1,425 patients. These cases of disseminated yeast infection occurred mostly in patients transferred with ARDS or septic shock in association with solid tumors or hematologic malignancy, a well-recognized association (35) but a category of patients excluded from this study. We routinely monitored urine, blood, and respiratory aspirate for yeasts. Only one patient in this entire study group (a placebo patient) was found to have candidemia (placebo group). The reason for the low frequency of yeast infection in this study is probably multifactorial and may be attributed to low frequency of steroid usage, tight control of blood sugars, and careful control of antibiotics and absence of cases of malignancy among these 71 septic patients. However, fluconazole prophylaxis has been shown to prevent intra-abdominal candidiasis in high-risk surgical patients (36) . Candidiasis may also be difficult to diagnose and may be associated with a high mortality equaling septic shock (37) . The hypothesis that the protective effect of fluconazole in septic shock in this study was unrelated to its antifungal activity is supported by our experimental studies in animals which showed a highly significant protective effect of fluconazole in rats with endotoxic shock induced by fecal peritonitis whereas other antifungal drugs including ketoconazole, itraconazole, and miconazole completely failed to reduce the organ failure and mortality in these animals (unpublished observations). There is only one other antifungal agent, namely ketoconazole, which has been shown to offer a significant protective effect in a nonfungal condition often associated with sepsis, i.e., ARDS (15) . Ketoconazole is thought to achieve this protection by thromboxane synthetase inhibition (18) . The mechanism of action of fluconazole in protecting patients in septic shock must be quite different from that of ketoconazole because it is virtually devoid of thromboxane synthetase inhibition (14) .
Zervos et al. (21) have shown greatly increased bactericidal activity of neutrophils, acting via a noncytokine-mediated pathway (22) , when exposed to fluconazole that may in turn lead to a decrease in overwhelming bacterial load and containment of bacteria at the focus of infection. The bactericidal activity of fluconazole was attributed to the binding of the drug at cell surface receptors and upregulation of intracellular signaling pathways leading to enhanced oxygen free radical release and chemotaxis (22) .
Neutrophils have been widely implicated in nonspecific host defense and tissue damage in clinical and experimentally induced endotoxic shock (38) . Neutrophils produce reactive oxygen metabolites damaging vascular endothelium directly and releasing granular enzymes (39) . Neutrophils also cause capillary plugging (39) . Neutrophil adherence in the microvasculature is considered one of the crucial steps in the production of septic shock with resultant cellular injury and multiple organ dysfunction (40) and moreover was shown in an animal model with fecal peritonitis to be directly proportional to the bacterial load (41) . Lipopolysaccharide has profound effects on both the number and functional capacity of neutrophils in the systemic circulation. There is a marked neutropenia resulting from sequestration of neutrophils caused by endothelial adherence within the pulmonary capillary bed after administration of lipopolysaccharide (42) . A leukocyte recruitment inhibitor (NPC 15669) with the ability to prevent neutrophil adherence to vascular endothelial cells (43) and inhibit degranulation of activated neutrophils (44) has been shown to reduce mortality in a rat model of sepsis (45) . In our laboratory, using an experimental model of septic shock in rats, fluconazole markedly reduced myeloperoxidase activity, a reliable marker of neutrophil sequestration (46) , in lung tissue in a dose-dependent manner (unpublished observations). Thus, fluconazole may have an action in blocking the neutrophil-endothelial adhesion interaction as well as modifying neutrophil recruitment and function. This observation may explain the higher neutrophil counts in fluconazole compared with placebotreated patients in our study.
The biochemical action of fluconazole should be considered as an explanation for its beneficial effects. The target for azole drugs is the fungal ERG11 gene product CYP51, lanosterol 14 ␣-demethylase. Disabling this enzyme causes ergosterol depletion, rendering the fungal cell vulnerable to further membrane damage (47) . The bis-triazole fluconazole is a potent inhibitor of CYP2C9 and CYP3A4 as revealed by inhibition of the oxidation of numerous drugs (48 -50) . In view of the affinity of fluconazole for CYP enzymes, it seems possible that its beneficial effects in intra-abdominal sepsis may be attributed to inhibition of as yet unidentified members of this large family of enzymes. Although survival in the fluconazoletreated patients, both pneumonia and intra-abdominal sepsis patients, with septic shock was significantly higher than in the placebo group of patients, the survival rates in the two clinical groups (i.e., intra-abdominal sepsis and pneumonia) receiving fluconazole showed a difference in response (Table 7) . A possible explanation for these differences in the two clinical groups (i.e., intra-abdominal sepsis and nosocomial pneumonia) studied, may be provided by the recent observation that the onset of septic shock in a sepsis model in rabbits was shown to be associated with a paradoxic lack of neutrophils in the peritoneal cavity (51) . The absence of neutrophils in the peritoneum was attributed in part to lysis of intraperitoneal neutrophils evidenced by free myeloperoxidase in the peritoneal cavity produced as a result of induced rapid death of normal rabbit neutrophils. Lungs are more effective than the peritoneum in containing infection and in compartmentalizing the inflammatory response (51) . High concentrations of bacteria were associated with paradoxic absence of neutrophils in the peritoneal cavity, local bacterial proliferation, development of septic shock, and lung injury. The failure of the peritoneal neutrophil response to high doses of bacteria contrasts with prior findings in a rabbit model of pneumonia (52) in which neutrophil recruitment occurred in the lungs of all rabbits with pneumonia even at the highest bacterial loads. Poor containment of infection in the peritoneal cavity is also supported by anatomical factors. The peritoneal epithelia contain pores that may allow bacteria access to the systemic circulation (53) whereas alveolar epithelia form a tight barrier (54) and prevent bacterial entry into the circulation. Finally, it has been postulated that there may be important differences in the response to bacteria of the local macrophage and neutrophil populations of the alveoli and peritoneum (54) .
CONCLUSION
The development of organ failure and mortality in septic shock attributed to intra-abdominal sepsis but not nosocomial pneumonia was significantly reduced by fluconazole given intravenously. The mechanism of action of fluconazole in reducing multiple organ dysfunction in this group of patients may be mediated by modulation of neutrophil adhesion as well as increased recruitment and improved function of these cells. Because of the significant reduction in mortality found in this study, we believe that a multi-center trial using fluconazole in a double-blind randomized manner in early septic shock attributed to intra-abdominal sepsis is required to validate our findings. Septic shock from intra-abdominal sepsis is well known to be associated with the highest multiple organ dysfunction and mortality (55) and therefore confirmed benefit in this group of patients would be a major advance in treatment.
